- Clinical Interests
- Interventional procedures
- Diagnostic imaging
- Clinical trials
- Medical Education
- MD, University of Heidelberg Medical School
- PhD, University of Heidelberg Medical School
- Residency, Massachusetts General Hospital
- Board Certifications
- Diagnostic Radiology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Patient Age Group
Dr. Weissleder is a founding member of the Society for Molecular Imaging Research for which he served as President in 2002. His work has been honored with numerous awards including the Millenium Pharmaceuticals Innovator Award (2003), the J. Taylor International Prize in Medicine (2004), the AUR Memorial Award, the ARRS President's Award, The Society for Molecular Imaging Lifetime Achievement Award, the Academy of Molecular Imaging 2006 Distinguished Basic Scientist Award and the 2008 RSNA Outstanding Researcher Award. Most recently (2009), Dr. Weissleder was also elected as a new member of the United States National Academy of Sciences Institute of Medicine (IOM).
- Research Summary
- My laboratory has three major areas of interest: 1) high-resolution microscopic imaging to study cancer treatment in vivo; 2) Using bioorthogonal chemistries to analyze intracellular protein networks involved in the molecular pathogenesis of complex human diseases to identify novel imaging and therapeutic targets; 3) Development of novel miniaturized sensing technologies (chips) for real-time high-throughput analysis of problems in biology.
MGH and Harvard Medical School faculty gathered May 19 at the medical school to celebrate the newly established Thrall Family Professorship in Radiology, named in honor of Jim Thrall, MD, and its first incumbent, Ralph Weissleder, MD, PhD, director of the MGH Center for Systems Biology.
A handheld diagnostic device that MGH investigators first developed to diagnose cancer has been adapted to rapidly diagnose tuberculosis and other important infectious bacteria.
Researchers affiliated with the Massachusetts General Hospital Department of Radiology have developed a simple, noninvasive way to detect early cancer by using new technology to look at a component in the blood.
A novel miniature diagnostic platform using nuclear magnetic resonance technology is capable of detecting minuscule cell particles known as microvesicles in a drop of blood. Detecting microvesicles shed by cancer cells could prove a simple means for diagnosing cancer or monitoring treatment response.
A heart attack doesn't just damage heart muscle tissue by cutting off its blood supply, it also sets off an inflammatory cascade that worsens underlying atherosclerosis, actively increasing the risk for a future heart attack, a new study finds.
Dr. Ralph Weissleder and his colleagues at Massachusetts General Hospital have developed a miniaturized nuclear magnetic resonance scanner, or micro-NMR to effectively increase both the speed and accuracy of tumor diagnoses.
The magnetic nanoparticle technology used in the device was developed by Ralph Weissleder, a professor at Harvard Medical School and director of the Center for Systems Biology at Massachusetts General Hospital in Boston.
55 Fruit Street
Boston MA, 02114-2696